Hereditary Resistance to 1,25-Dihydroxyvitamin D: Clinical and Radiological Improvement during High-Dose Oral Calcium Therapy

1986 ◽  
Vol 24 (4) ◽  
pp. 280-287 ◽  
Author(s):  
Nadia Sakati ◽  
Nicholas J.Y. Woodhouse ◽  
Nancy Niles ◽  
Harb Harfi ◽  
Donald A. de Grange ◽  
...  
Keyword(s):  
High Dose ◽  
Oral Calcium ◽  
Dihydroxyvitamin D ◽  
1,25 Dihydroxyvitamin D ◽  
Dose Oral

scholarly journals Serum 1,25-Dihydroxyvitamin D as a Biomarker of the Absence of Hypercalciuria in Postsurgical Hypoparathyroidism

2016 ◽  
Vol 102 (1) ◽  
pp. 259-266 ◽  
Author(s):  
Luis García-Pascual ◽  
María José Barahona ◽  
Verónica Perea ◽  
Rafael Simó
Keyword(s):  
Serum Calcium ◽  
Characteristic Curve ◽  
Linear Regression Analysis ◽  
Predictive Biomarkers ◽  
Multiple Linear Regression Analysis ◽  
Calcium Excretion ◽  
Cross Sectional ◽  
Oral Calcium ◽  
Dihydroxyvitamin D ◽  
1,25 Dihydroxyvitamin D

Abstract Context: Hypercalciuria is an adverse event of postsurgical hypoparathyroidism treatment that can lead to renal complications. The collection of 24-hour urine to detect hypercalciuria is often considered unreliable. Objective: The purpose of this study was to find useful predictive biomarkers of hypercalciuria in patients with permanent postsurgical hypoparathyroidism receiving treatment with oral calcium and calcitriol supplements. Design and Setting: The investigation was designed as a prospective cross-sectional study. An outpatient hospital clinic served as the study setting. Patients: Fifty-four consecutive observations were made of 34 stable outpatients with postsurgical hypoparathyroidism taking oral calcium and calcitriol supplements, and 17 adult controls without hypoparathyroidism. Intervention: There were no interventions. Main Outcome Measure: Hypercalciuria was defined as 24-hour urine calcium >300 mg. Results: Patients without hypercalciuria (n = 21) vs those with hypercalciuria (n = 33) had lower levels of serum 1,25-dihydroxyvitamin D (33.5 ± 11.9 pg/mL vs 45.8 ± 9.5 pg/mL; P < 0.001), similar albumin-corrected serum calcium (8.3 ± 0.5 vs 8.6 ± 0.5 mg/dL; P = nonsignificant), and serum parathyroid hormone (12.5 ± 5.7 vs 10.7 ± 6.8 pg/mL; P = nonsignificant). Multiple linear regression analysis showed an independent relationship between 1,25-dihydroxyvitamin D and urinary calcium excretion (B = 6.2 ± 1.423; P < 0.001). A cutoff value of 33.5 pg/mL for serum 1,25-dihydroxyvitamin D to predict the absence of hypercalciuria had 100% sensitivity and 63.6% specificity, and the area under the receiver operating characteristic curve was 0.797. No patients with serum 1,25-dihydroxyvitamin D levels of <33.5 pg/mL presented with hypercalciuria, regardless of the level of albumin-corrected serum calcium. Conclusions: Routine measurement of serum 1,25-dihydroxyvitamin D may be useful as a biomarker to predict the absence of hypercalciuria in patients with permanent postsurgical hypoparathyroidism who are receiving treatment with oral calcium and calcitriol supplements.

scholarly journals High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice

2016 ◽  
Vol 76 (3) ◽  
pp. 176-181 ◽  
Author(s):  
Máté` Fort Molnár ◽  
Rita Török ◽  
Evelin Sümegi ◽  
László Vécsei ◽  
Péter Klivényi ◽  
...  
Keyword(s):  
Transgenic Mice ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
High Dose ◽  
Dihydroxyvitamin D ◽  
1,25 Dihydroxyvitamin D

Effect of oral calcium supplementation on intracellular calcium and plasma renin in men

1995 ◽  
Vol 146 (3) ◽  
pp. 421-429 ◽  
Author(s):  
P Lijnen ◽  
V Petrov
Keyword(s):  
Plasma Concentration ◽  
Intracellular Calcium ◽  
Calcium Supplementation ◽  
Plasma Renin ◽  
Normal Male ◽  
Calcium Excretion ◽  
Oral Calcium ◽  
Dihydroxyvitamin D ◽  
1,25 Dihydroxyvitamin D ◽  
Elemental Calcium

Abstract A double-blind, placebo-controlled parallel study was conducted on the effect of a high daily oral calcium supplementation of 1 g elemental calcium, given twice daily for 16 weeks in normal male subjects, on plasma renin, aldosterone, kallikrein, cGMP, cAMP and calciotropic hormones, intracellular calcium concentrations and plasma total and ionized calcium. After a 1-month run-in period on a limited use of dairy products, the subjects (n=32) were allocated to a placebo or a calcium group. Placebo or 1 g elemental calcium was administered twice daily in the morning and evening for 16 weeks. All subjects were investigated at baseline and after 1, 2, 4, 8 and 16 weeks of placebo or calcium administration. A decreased intraerythrocyte and intraplatelet Ca2+ concentration was observed in the calcium-treated subjects. Compared with the placebo group, an increase in the plasma renin activity (PRA) in the calcium group was observed after 4, 8 and 16 weeks of oral calcium administration. However, plasma aldosterone and urinary excretion of aldosterone, kallikrein, cGMP and cAMP were not changed during calcium administration. Oral calcium supplementation in these men was also accompanied by a reduction in the plasma concentration of intact parathyroid hormone and 1,25-dihydroxyvitamin D3, an increase in 24-h urinary calcium excretion but no change in the plasma total Ca2+ concentration, serum ionized Ca2+ level and plasma phosphate or 25-hydroxyvitamin D3. Lacidipine tended to increase PRA in the placebo-treated subjects and to decrease it in the calcium-treated subjects: this difference in lacidipine effect between the placebo and calcium group was significant (P<0·05). Our data show that the increase in PRA observed in men during oral calcium supplementation is accompanied by a reduction in the intracellular free and total Ca2+ concentration in platelets and erythrocytes and by a decrease in the plasma concentration of intact parathormone and 1,25-dihydroxyvitamin D3. Journal of Endocrinology (1995) 146, 421–429

Sign in / Sign up

Export Citation Format

Share Document